The federal regulatory debate over hemp-derived cannabinoids is moving into a new phase.
For manufacturers, the question is no longer simply whether a cannabinoid comes from hemp or marijuana. The more consequential question is which federal regulatory framework will govern the finished product once a cannabinoid enters a food, beverage, supplement, or other consumer product.
The Food and Drug Administration already has substantial authority over cannabis-derived products under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The 2018 Farm Bill removed hemp from the federal Controlled Substances Act under specified conditions, but it did not remove FDA jurisdiction over hemp-derived products that fall within the agency’s regulatory authority.
At the same time, FDA has made clear that its existing food and dietary-supplement frameworks are not, in its view, appropriate for CBD. In January 2023, the agency said a new regulatory pathway would be needed and indicated that it was prepared to work with Congress to develop one.
That leaves the industry facing an unusual situation: FDA already regulates the relevant products under existing law, but the agency has also said that the existing pathways do not adequately address the cannabinoid marketplace.
Congress is now considering whether to create a more specific federal framework.
For extraction companies, ingredient manufacturers, CPG brands and investors, the outcome could fundamentally change how cannabinoid products are formulated, tested, manufactured, labeled and commercialized.
FDA Already Has Authority Over Cannabinoid Foods
One misconception in the hemp market is that the 2018 Farm Bill created a general federal authorization for hemp-derived products.
It did not.
The Farm Bill changed the federal definition of hemp and removed qualifying hemp from the Controlled Substances Act. However, Congress expressly preserved FDA’s authority under the FD&C Act. FDA therefore continues to regulate cannabis-derived ingredients and products that fall within the agency’s jurisdiction.
That distinction is particularly important for food manufacturers.
FDA currently states that THC and CBD cannot be marketed as dietary supplements under the agency’s interpretation of the FD&C Act. FDA also states that introducing food containing added THC or CBD into interstate commerce is prohibited under Section 301(ll), subject to the statutory framework and exceptions.
In other words, a product’s classification as “hemp-derived” does not by itself answer whether the finished product can legally be sold as a food or dietary supplement.
For manufacturers, there are effectively two separate questions:
Is the cannabinoid federally lawful as hemp?
And:
Is the intended use of that cannabinoid lawful under the FD&C Act?
Those questions can produce different answers.
CBD and THC Are Not Treated Like Ordinary Food Ingredients
FDA’s position is rooted partly in the statutory treatment of CBD and THC as drug-related substances.
FDA states that THC and CBD are excluded from the dietary supplement definition under Section 201(ff)(3)(B) of the FD&C Act. The agency also states that CBD and THC cannot be added to conventional foods sold in interstate commerce under Section 301(ll), because of their status under the drug provisions of federal law.
That creates a significant regulatory distinction for CPG companies.
A manufacturer developing a conventional beverage normally evaluates ingredients through food-additive, GRAS, labeling and food-safety frameworks.
A manufacturer adding CBD cannot simply assume that the same process applies.
FDA addressed this directly in 2023, concluding that the existing food and dietary-supplement pathways were not appropriate for CBD. The agency cited unresolved safety questions and limitations in its existing authorities for managing the risks associated with widespread CBD consumption.
The agency specifically identified potential tools for a future framework, including:
- Clear labeling
- Contaminant controls
- CBD content limits
- Minimum purchase ages
- Other measures designed to reduce risks to consumers
Those concepts provide an important window into what a future regulated cannabinoid market could look like.
What Would an FDA-Controlled Cannabinoid Market Look Like?
There is currently no enacted federal system that simply places all consumable cannabinoids into a dedicated FDA product category.
However, Congress has considered legislation that would move in that direction.
One significant example is the Hemp Enforcement, Modernization, and Protection Act, H.R. 7212, introduced in January 2026. The bill would amend the FD&C Act to create a federal framework specifically for cannabinoid hemp products. It was referred to the House Energy and Commerce Committee and, as of September 2026, remains legislation rather than current law.
The proposal illustrates the types of requirements manufacturers could encounter under a dedicated federal system.
Its framework includes concepts such as:
- Product listing
- Definitions for cannabinoid products
- Manufacturing and testing requirements
- Labeling standards
- Minimum age requirements
- Packaging requirements
- FDA oversight
- Enforcement authorities
The bill also contemplates different categories of cannabinoid products, including oral, inhalable and topical products.
That is important because it suggests that a future system would not necessarily treat a gummy, beverage, vape, topical cream and dietary supplement as identical products.
Instead, regulation could become product-category specific.
A Future System Could Look More Like a CPG Regulatory Program
If Congress establishes a dedicated federal cannabinoid pathway, manufacturers could see cannabinoid products move closer to the regulatory structure already familiar to the broader food, beverage and consumer-products industries.
A mature system could potentially involve several layers.
Product Registration or Listing
Manufacturers could be required to identify products with FDA before or after commercialization.
H.R. 7212, for example, proposes cannabinoid hemp product listings for responsible parties.
For large brands, that would mean regulatory data becomes part of the product lifecycle rather than something handled only when an enforcement issue occurs.
Manufacturing Requirements
A federal cannabinoid framework could establish specific requirements for manufacturing operations and testing.
That could affect:
- Raw-material qualification
- Supplier approval
- Batch records
- Process controls
- Sanitation
- Environmental controls
- Equipment qualification
- Laboratory testing
- Finished-product release
- Traceability
The result would be a greater emphasis on repeatable manufacturing systems rather than simply obtaining a certificate of analysis for each batch.
Labeling
Cannabinoid products could eventually have standardized labeling requirements covering cannabinoid identity, content, serving information, warnings and other consumer disclosures.
This would have direct consequences for packaging development.
A formulation change could potentially trigger a labeling change, which could then affect packaging inventory, artwork approval, production scheduling and distribution.
Age and Packaging Controls
FDA’s 2023 CBD framework discussion specifically identified minimum purchase age and measures designed to prevent accidental ingestion by children as potential risk-management tools.
Packaging could therefore become an important component of compliance.
For products resembling ordinary food—particularly gummies, candies and beverages—manufacturers may face additional requirements designed to distinguish cannabinoid products from conventional foods.
The 2026 Legislative Debate Shows There Is More Than One Possible Model
The policy direction remains unsettled.
H.R. 7212 represents one approach: create a dedicated FDA framework for cannabinoid hemp products.
Another proposal, the Lawful Hemp Protection Act (H.R. 9830), was introduced in July 2026. The bill seeks to preserve lawful hemp commerce while addressing high-THC synthetic intoxicants and would establish a federal regulatory framework involving FDA and other federal agencies. It remains a proposal rather than enacted law.
These proposals matter even when they do not become law because they demonstrate the range of regulatory structures being considered.
For manufacturers, the important takeaway is that the eventual federal system could differ substantially from both today’s marketplace and the restrictions scheduled under existing hemp legislation.
Companies should therefore avoid designing long-term facilities or product portfolios around assumptions about a bill that has not passed.
The Hemp Definition Is Changing Too
The FDA question cannot be separated from the changing federal definition of hemp.
Public Law 119-37, enacted in November 2025, amended the federal hemp definition. Among other changes, the law moves toward a total-THC standard and excludes certain intermediate and final hemp-derived cannabinoid products. The amended definition also addresses cannabinoids that are not naturally produced by the cannabis plant or that are synthesized or manufactured outside the plant.
The revised definition was originally scheduled to take effect November 12, 2026.
That means manufacturers are simultaneously dealing with two related but distinct regulatory issues:
Agricultural and controlled-substance status:
Does the material qualify as hemp?
Food and consumer-product status:
Can the resulting ingredient or finished product legally be marketed for its intended use?
A manufacturer can satisfy one question and still have a problem with the other.
Why This Matters for Extraction Companies
For extraction businesses, the regulatory implications begin well before the finished product reaches a retail shelf.
Consider a typical material flow:
Hemp biomass → extraction → purification → cannabinoid ingredient → formulation → finished product → packaging → distribution
Every stage creates a potential compliance checkpoint.
The extraction facility may need to document the source and identity of the biomass.
The processor may need to establish specifications for the intermediate extract.
The formulation operation needs to know precisely how much cannabinoid enters each batch.
The finished-product manufacturer needs validated testing and release procedures.
And the brand needs documentation supporting the label and claims appearing on the package.
This creates an increasingly important distinction between ingredient quality and regulatory status.
A highly pure extract is not automatically a lawful food ingredient.
Likewise, a compliant hemp input does not automatically make every downstream consumer product lawful.
Testing Programs Will Become More Important
A more formal FDA framework would almost certainly increase the importance of analytical testing and quality systems.
FDA has previously raised concerns about cannabinoid products whose actual contents did not match their labels and about the presence of other potentially harmful compounds.
For manufacturers, this creates several practical priorities.
Raw-Material Testing
Companies need confidence in the identity and cannabinoid profile of incoming materials.
In-Process Controls
Manufacturers should understand how cannabinoids behave during extraction, concentration, mixing, heating and other processing steps.
Finished-Product Testing
Testing should verify that the product meets established specifications before release.
Laboratory Qualification
As cannabinoid regulations become more formal, laboratories and analytical methods become part of the quality system rather than merely an outside service.
Data Integrity
Companies should be able to connect laboratory results to specific batches, production records, raw materials and finished goods.
For regulated CPG operations, the objective is not simply to generate a favorable laboratory result.
The objective is to create a defensible chain of evidence showing how the product was manufactured and why it was released.
GMP and HACCP Programs Could Become Central to Cannabinoid Manufacturing
A future FDA-regulated market would also raise the importance of established food and manufacturing quality systems.
Depending on the product category and final regulatory framework, manufacturers could need to integrate cannabinoid-specific controls into existing:
- Good Manufacturing Practices
- Preventive controls
- HACCP programs
- Supplier qualification
- Sanitation programs
- Allergen controls
- Environmental monitoring
- Traceability systems
- Complaint handling
- Recall procedures
- Corrective and preventive action programs
The important point for facility operators is that regulatory compliance cannot be separated from physical plant design.
A company cannot create an effective quality system if the facility makes material segregation, sanitation, personnel flow or traceability unnecessarily difficult.
Facility Design Could Change With the Regulatory Model
This is where the FDA question becomes a facility-engineering issue.
A manufacturer building a cannabinoid production facility today may expect to operate for 10, 20 or more years.
Federal cannabinoid policy could change multiple times during that period.
Facilities should therefore consider flexibility.
That can include:
Segregated material flows.
Different ingredients and product categories may require clear identification and separation.
Flexible production areas.
Manufacturing spaces capable of supporting multiple formulations can reduce dependence on one product category.
Adequate sampling areas.
Testing programs become easier when sampling can be performed consistently without disrupting production.
Controlled storage.
Raw materials, intermediates and finished products should have defined storage conditions and status identification.
Packaging flexibility.
Future labeling, child-safety or product-identification requirements could affect packaging equipment and workflows.
Utilities and process capacity.
Extraction and formulation systems should be evaluated for their ability to support future product changes.
The goal is not to predict the exact regulation that Congress will eventually enact.
The goal is to avoid building a facility that can operate efficiently under only one regulatory scenario.
The Food-Safety Question May Become More Important Than the Hemp Question
As cannabinoid products increasingly resemble conventional CPG products, regulators will have to address familiar food-safety concerns alongside cannabinoid-specific issues.
A gummy is still a food-manufacturing process.
A cannabinoid beverage still has water, ingredients, packaging and shelf-life considerations.
A functional food still requires control of microbial, chemical and physical hazards.
The cannabinoid ingredient adds another layer.
FDA’s broader food program is already placing significant attention on food-ingredient oversight. In August 2026, FDA proposed changes intended to strengthen oversight and transparency around substances claimed to be Generally Recognized as Safe.
That development is relevant beyond CBD.
It signals an environment in which manufacturers should expect greater attention to the scientific basis, intended use, specifications and documentation supporting ingredients placed into the food supply.
What Manufacturers Should Do Now
The regulatory outcome remains unsettled, but companies do not need to wait to improve their operations.
- Separate Hemp Compliance From Product Compliance
Create two distinct regulatory assessments.
One should address whether the source material qualifies as hemp.
The second should address whether the intended finished-product use complies with FDA and applicable state requirements.
- Build a Cannabinoid Ingredient Inventory
Document every cannabinoid used in production, including:
- Source
- Extraction method
- Manufacturing method
- Chemical modifications
- Potency
- Specifications
- Testing
- Supplier
- Intended product applications
- Audit Product Claims
Review website copy, packaging, advertising and sales materials.
Therapeutic claims can create drug-related regulatory issues even when the underlying product is otherwise positioned as a consumer wellness product.
- Strengthen Batch Traceability
The ability to trace a finished package back to its formulation batch, cannabinoid ingredient, supplier and analytical results should be treated as a core manufacturing capability.
- Model Multiple Regulatory Scenarios
Companies should model what happens if:
- Current restrictions remain
- A dedicated FDA cannabinoid framework is enacted
- THC or intoxicating cannabinoid limits change
- Product registration becomes mandatory
- Testing requirements increase
- Age restrictions become federal
- State requirements remain more restrictive than federal requirements
Scenario planning is more useful than betting the business on one legislative outcome.
What Would FDA Oversight Mean for Investors?
A more formal federal system could also change how investors evaluate cannabinoid companies.
Revenue alone would provide an incomplete picture.
Due diligence could increasingly focus on:
- Regulatory exposure by SKU
- Dependence on particular cannabinoids
- Testing infrastructure
- Manufacturing documentation
- Product claims
- Supplier qualification
- State distribution footprint
- Facility flexibility
- Recall readiness
- Ability to reformulate
- Quality-system maturity
Companies with strong manufacturing controls may have an easier operational transition than companies whose compliance processes depend heavily on informal supplier documentation or batch-by-batch workarounds.
That is not a prediction about which businesses will succeed.
It is a recognition that regulatory change can alter the underlying cost structure and operating requirements of a manufacturing business.
FDA May Not Become the Only Regulator
Even if Congress creates a dedicated FDA cannabinoid framework, manufacturers should not expect the rest of the regulatory system to disappear.
USDA would continue to have responsibilities related to agricultural production and hemp programs.
FDA would retain its role under the FD&C Act.
States could continue imposing additional requirements within their authority.
Other federal agencies could have jurisdiction depending on the product, facility, claims and distribution model.
The future market is therefore more likely to involve coordinated federal and state oversight than a single regulator controlling every aspect of the supply chain.
For manufacturers, that means regulatory mapping will remain essential.
The Industry Is Moving Toward a More Formal Compliance Model
The biggest change may not be a single THC threshold or one new FDA rule.
It may be the gradual transition from a relatively fragmented cannabinoid marketplace toward a conventional regulated manufacturing environment.
FDA already operates a Cannabis Product Committee responsible for developing and implementing cross-agency strategy and policy related to cannabis products. The agency also continues to maintain warning-letter and enforcement resources covering CBD and other cannabis-derived products.
Meanwhile, Congress is actively considering legislation that would establish dedicated federal rules for cannabinoid products.
Taken together, those developments indicate that federal oversight of consumable cannabinoids is likely to remain a major policy and manufacturing issue.
What the final system looks like remains unresolved.
Conclusion: The Regulatory Question Is Bigger Than CBD
FDA already has authority over foods, beverages and dietary supplements containing cannabis-derived compounds. The 2018 Farm Bill did not create an exemption from the FD&C Act. FDA currently states that THC and CBD cannot be marketed as dietary supplements and that food containing added THC or CBD cannot lawfully enter interstate commerce under the agency’s current interpretation of federal law.
At the same time, FDA has acknowledged that its existing food and supplement frameworks are not well suited to CBD and has called for a new regulatory pathway developed with Congress.
Congressional proposals introduced in 2026 demonstrate what such a framework could involve: product listings, manufacturing and testing requirements, labeling, age restrictions, packaging standards and expanded federal enforcement. But those proposals remain proposals, not current law.
For manufacturers, the prudent approach is therefore not to assume that FDA will become the sole regulator of cannabinoids—or that today’s fragmented market will continue indefinitely.
Instead, companies should prepare for a market in which ingredient identity, product formulation, testing, manufacturing controls, labeling, facility design and traceability are all part of the regulatory equation.
The companies best positioned for that environment will need more than a compliant extract.
They will need a compliant system for turning that extract into a consistent, documented and market-ready consumer product.
